Crinetics Pharmaceuticals (CRNX) EBITDA: 2017-2025
Historic EBITDA for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to -$129.5 million.
- Crinetics Pharmaceuticals' EBITDA fell 73.62% to -$129.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.9 million, marking a year-over-year decrease of 53.79%. This contributed to the annual value of -$298.4 million for FY2024, which is 42.36% down from last year.
- According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' EBITDA is -$129.5 million, which was down 11.64% from -$116.0 million recorded in Q2 2025.
- Over the past 5 years, Crinetics Pharmaceuticals' EBITDA peaked at -$22.9 million during Q1 2021, and registered a low of -$129.5 million during Q3 2025.
- For the 3-year period, Crinetics Pharmaceuticals' EBITDA averaged around -$77.2 million, with its median value being -$74.4 million (2024).
- Data for Crinetics Pharmaceuticals' EBITDA shows a maximum YoY plummeted of 73.62% (in 2025) over the last 5 years.
- Crinetics Pharmaceuticals' EBITDA (Quarterly) stood at -$26.1 million in 2021, then slumped by 68.22% to -$43.9 million in 2022, then tumbled by 32.66% to -$58.3 million in 2023, then crashed by 40.19% to -$81.7 million in 2024, then plummeted by 73.62% to -$129.5 million in 2025.
- Its last three reported values are -$129.5 million in Q3 2025, -$116.0 million for Q2 2025, and -$95.7 million during Q1 2025.